HHS secretary RFK Jr. said that he would “shut the revolving door to reestablish public trust” in the department.

has confirmed that its director of the Centre for Drug Evaluation and Research (CDER), Patrizia Cavazzoni, has announced her resignation ahead of Donald Trump’s inauguration on 20 January.

A federal pharmaceutical testing facility in St. Louis will remain open, despite appearing on DOGE’s list of scheduled office ...

The Senate hearing for FDA Commissioner nominee Marty Makary comes after President Trump's NIH pick, Jay Bhattacharya, was ...

The user fee program framework includes trigger rates that must be met in order for the FDA to access the funding. Without enough staff at the CDER, which receives user fees, the FDA could find ...

Cavazzoni was the head of the FDA’s Center for Drug Evaluation and Research (CDER), from 2020 until her departure in January. She was one of several top FDA officials who left the agency ahead ...

While these layoffs affected areas such as CDRH (Center for Devices and Radiological Health) and the Human Foods Program (HFP), it’s worth noting that CDER (Center for Drug Evaluation and ...

Trump has made major cuts across several federal health agencies—including the FDA—in the name of government efficiency, resulting in thousands of layoffs. After taking the top spot at CDER ...

MATTB provides assistance and training through outreach to industry. A: CDER's Division of Drug Information (DDI) serves as a focal point for public inquiries regarding human drug products.

Per the FDA: The DRMB is a cross-CDER governance board responsible for three key objectives: (1) facilitating and coordinating decisions around major product safety issues, (2) providing clear and ...

Patrizia Cavazzoni was formerly director of the FDA’s Center for Drug Evaluation and Research (CDER) from 2020 until January, when she resigned just ahead of President Trump’s return to office.